Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Janet Woodcock

- PMLiVE

Teva’s asthma treatment Cinqaero set for European approval

CHMP backs the antibody therapy for eosinophilic asthma

- PMLiVE

Ariad files early marketing application for brigatinib

Second-line lung cancer therapy could be on the market by early 2017

Shire Basingstoke

Shire receives FDA nod for self-infusion of Glassia

The company has also struck a deal with Pfizer to expand its GI portfolio

- PMLiVE

Updated EMPA-REG data show Jardiance also protects kidney

Boehringer Ingelheim and Lilly’s drug is the first to show positive impact on kidney damage

- PMLiVE

Teva suspends migraine patch on burn reports

FDA issues safety alert and instigates investigation into Zecuity

- PMLiVE

FDA approves first cholera vaccine in US

PaxVax’s oral vaccine Vaxchora will be launched by September

- PMLiVE

FDA panel backs Pfizer and Teva abuse-resistant painkillers

Recommends long-acting opioid analgesics Troxyca ER and Vantrela ER for approval

Biogen Idec building

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Once-monthly, self-administered Zinbryta ‘significantly’ reduces relapse rate

Teva Pharma logo

FDA turns down Teva’s Huntington’s disease drug

Has requested further analysis on certain metabolites of the chorea candidate

- PMLiVE

FDA gives green light for opioid addiction implant

Titan and Braeburn's Probuphine is first implant of its kind to win US approval

Sanofi reception

FDA panel backs Sanofi’s insulin/GLP-1 agonist combo

iGlarLixi secures endorsement despite concern over its dosing and delivery device

EISAI

Eisai gets green light for Lenvima in kidney cancer

New drug awarded breakthrough and priority review status by FDA in RCC

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links